Person: OKAY, GÜLAY
60 results
Search Results
Now showing 1 - 10 of 60
Publication Frequencies and antibiotic susceptibilities of Pseudomonas spp. and Acinetobacter spp. isolated from blood culture: 7-year trend analysis of Pseudomonas spp and Acinetobacter spp bacteremias(2020-01-01T00:00:00Z) BOLUKÇU, SİBEL; OKAY, GÜLAY; OKAY, GÜLAYPublication Spondilodiskitlere laboratuvar yaklaşım(2019-06-29T00:00:00Z) OKAY, GÜLAY; OKAY, GÜLAYPublication Evaluation of hepatitis B vaccine efficacy and factors affecting vaccine nonresponse in patients receiving anti-tumor necrosis factor agents.(2020-07-14T00:00:00Z) Akkoyunlu, Y; Okay, G; Bolukcu, S; Betül, Uslu; Meric, Koc; OKAY, GÜLAY; BİBERCİ KESKİN, ELMAS; AKKOYUNLU, YASEMİN; USLU, AYŞE BETÜLPublication Results of nucleos(t)ide analog treatment discontinuation in hepatitis b e-Antigen-negative chronic hepatitis b: Nucstop study(2024-01-01) Kiremitci S.; Kochan K.; SEVEN G.; Keskin E. B.; OKAY G.; AKKOYUNLU Y.; Koc M. M.; SÜMBÜL B.; ŞENTÜRK H.; KİREMİTÇİ, SERCAN; KOÇHAN, KORAY; SEVEN, GÜLSEREN; OKAY, GÜLAY; AKKOYUNLU, YASEMİN; SÜMBÜL, BİLGE; ŞENTÜRK, HAKANBackground/Aims: This study aims to investigate the effects of nucleos(t)ide analogs (NAs) discontinuation in eligible patients in accordance with the Asian Pacific Association for the Study of the Liver hepatitis B guideline and the factors affecting clinical and virological relapses. Materials and Methods: In this prospectively designed study, hepatitis B e antigen (HBeAg)-negative chronic hepatitis B patients who were followed up between 2012 and 2019 were evaluated and 57 patients were included. All participants enrolled the study were HBeAgnegative status at NA initiation. Results: The median age of the patients was 49 (29-72) years and 24 (42%) were females. The median treatment duration was 96 (36-276) months and patients were followed for a median duration of 27 months. Sixteen patients had a previous history of NA switch, and thirteen of these patients had a history of lamivudine resistance. Thirty-eight of 57 patients (66%) developed an elevated hepatitis B virus deoxyribonucleic acid level of 2000 IU/mL at least once, defined as virological relapse and 23 (60%) of them, experienced clinical relapse. Thirty-one of 57 patients were re-Treated during the follow-up, and hepatitis B surface antigen (HBsAg) loss occurred among 4 (7%) patients. All patients who experienced HBsAg loss had a history of lamivudine resistance (P = .002). Conclusion: Despite receiving NAs suppression therapy for a long time, HBsAg loss occurs rarely. Although it was not life-Threatening, most patients experienced relapses and treatment should be restarted. In our study, whether it is a coincidence that all patients with HBsAg loss are patients in whom NAs are used sequentially due to lamivudine resistance is an issue that needs to be further investigated.Publication Koruyucu Hekimlikte Aşı(2021-12-01T00:00:00Z) Okay, Gülay; OKAY, GÜLAYPublication Discordance between Serum Neutralizing Antibody Titers and the Recovery from COVID-19(2020-09-25T00:00:00Z) Koç, Mm; Kalkan, Yazıcı; Çetin, Nesibe Selma; Doymaz, Mz; Sümbül, B; Durdu, B; YAZICI, MERVE; MERİÇ KOÇ, MELİHA; ÇETİN, NESİBE SELMA; KARAASLAN, ELİF; OKAY, GÜLAY; DURDU, BÜLENT; SÜMBÜL, BİLGE; DOYMAZ, MEHMET ZIYAThe recent pandemic of COVID-19 has caused a tremendous alarm around the world. Details of the infection process in the host have significant bearings on both recovery from the disease and on the correlates of the protection from the future exposures. One of these factors is the presence and titers of neutralizing Abs (NAbs) in infected people. In the current study, we set out to investigate NAbs in the recovered subjects discharged from the hospital in full health. Serum samples from a total of 49 documented consecutive COVID-19 subjects were included in the study. All the subjects were adults, and serum samples collected during the discharge were tested in viral neutralization, enzyme immunoassay (EIA), and Western immunoblot tests against viral Ags. Even though a majority of the recovered subjects had raised significant NAb titers, there is a substantial number of recovered patients (10 out of 49) with no or low titers of NAbs against the virus. In these cohorts as well as in patients with high NAb titers, viral Ag binding Abs were detectable in EIA tests. Both NAb titers and EIA detectable Abs are increased in patients experiencing a severe form of the disease, and in older patients the Ab titers were heightened. The main conclusion is that the recovery from SARS-CoV-2 infection is not solely dependent on high NAb titers in affected subjects, and this recovery process is probably produced by a complex interplay between many factors, including immune response, age of the subjects, and viral pathology.Publication Enfeksiyöz Spondilodiskitler: Bir üniversite hastanesinde son 7 yılda izlenen hastaların değerlendirilmesi(2018-05-13T00:00:00Z) OKAY, GÜLAY; OKAY, GÜLAYPublication Utility of Rapid Antibody Test for Screening COVID-19 Among Healthcare Professionals(2020-10-01T00:00:00Z) Okay, Gulay; Kacmaz, Asiye Bahar; Sumbul, BİLGE; Bolukcu, Sibel; Akkoyunlu, Yasemin; Meric Koc, Meliha; SÜMBÜL, BİLGE; OKAY, GÜLAY; DURDU, BÜLENT; AKKOYUNLU, YASEMİNObjective: This study aims to assess the effectivity of a rapid antibody test on detecting the occupational exposure in healthcare professionals who have been working in a pandemic hospital since the initial cases were seen in our country.Publication İmmünsüpresif ilaç kullanan hastalarımızda aşılama oranı ve Hepatit B aşı etkinliği(2019-04-07T00:00:00Z) OKAY, GÜLAY; BİBERCİ KESKİN, ELMAS; MERİÇ KOÇ, MELİHA; OKAY, GÜLAY; BİBERCİ KESKİN, ELMAS; MERİÇ KOÇ, MELİHAPublication COVID-19-da Hastaneye Başvuru Sırasında Nörolojik Semptomlar: Tek Merkez Deneyemi- Ön Veriler(2021-01-15T00:00:00Z) Uslu, Ferda; Okay, Gülay; Meriç Koç, Meliha; Gürsoy, Azize Esra; USLU, FERDA; OKAY, GÜLAY; MERİÇ KOÇ, MELİHA; GÜRSOY, AZIZE ESRA